Late-onset Pompe disease (LOPD) is a rare metabolic disease with an age of onset of ≥ 1 year. Patients experience steady degeneration of respiratory and skeletal muscles due to acid alpha-glucosidase deficiency, which can lead to decreased mobility as well as respiratory weakness. LOPD is treated by enzyme replacement therapy (ERT). The objective of this observational study is 1) to capture real world mobility data and daily activity through a commercially available wearable device in LOPD patients.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...